---
id: bioptic-ai-agents
slug: bioptic-ai-agents
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-01-27
researcher: AI Assistant
version: 1.1
name: Bioptic AI Agents Platform
description: Vertical AI agents platform for the biopharmaceutical industry that automates processes of asset scouting, evaluation, and licensing of drug assets globally. The platform combines molecular data, clinical evidence, and deal economics into a unified AI-driven decision-making system.
mission: To transform biopharmaceutical asset discovery, evaluation, and licensing through vertical AI agents that automate and accelerate the entire process. The company aims to combine cutting-edge AI technologies with deep industry knowledge to scale scientific research and development, enabling pharmaceutical companies to identify, evaluate, and license drug assets more efficiently and accurately.
entity_data:
  name: Bioptic
  focus: Development of vertical AI agents for the biopharmaceutical industry, automating processes of asset scouting, evaluation, and licensing of drug assets globally. The platform combines molecular data, clinical evidence, and deal economics into a unified AI-driven decision-making system.
  status: operational
  website: "https://agents.bioptic.io"
  industry: Biotechnology, AI Software
  employees:
  as_of: 2025
  range: Not disclosed
  legal_name: Bioptic, Inc.
  headquarters:
  address: Not disclosed
  country: USA
  alternative_website: "https://bioptic.io"
taxonomy:
  geography: USA
  ai_approach: []
  ai_technology:
  - Multi-Agent AI
  primary_focus:
  - AI-Driven Drug Discovery
  aging_approach:
  - Target Discovery
  target_biology:
  - General Aging/Longevity
  ai_architecture: []
  ai_specialization:
  - Multi-Agent AI
  development_stage: operational
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality: []
organizations:
  -
    name: Bioptic
    role: primary
    org_type: company
    legal_name: Bioptic, Inc.
    website: "https://agents.bioptic.io"
    status: operational
    role_description: Primary organization developing the BIOPTIC® AI Agents Platform
products:
  -
    name: OPT-LR42
    type: drug
    status: Discovery/Preclinical
    development_stage: preclinical
  -
    name: BIOPTIC® AI Agents Platform
    type: platform
    status: Operational
    development_stage: operational
links:
  -
    url: "https://bioptic.io/blog/lrrk2-patent"
    type: blog_post
    title: Bioptic LRRK2 Patent Blog Post
  -
    url: "https://bioptic.io/contact"
    type: website
    title: Bioptic Contact
  -
    url: "https://bioptic.io/pipeline"
    type: website
    title: Bioptic Pipeline
  -
    url: "https://bioptic.io/about"
    type: website
    title: Bioptic About
  -
    url: "https://bioptic.io/technology"
    type: website
    title: Bioptic Technology
  -
    url: "https://bioptic.io"
    type: website
    title: Bioptic - Official Website
---

# Bioptic AI Agents Platform

## Description

Vertical AI agents platform for the biopharmaceutical industry that automates processes of asset scouting, evaluation, and licensing of drug assets globally. The platform combines molecular data, clinical evidence, and deal economics into a unified AI-driven decision-making system.

## Mission

To transform biopharmaceutical asset discovery, evaluation, and licensing through vertical AI agents that automate and accelerate the entire process. The company aims to combine cutting-edge AI technologies with deep industry knowledge to scale scientific research and development, enabling pharmaceutical companies to identify, evaluate, and license drug assets more efficiently and accurately.

## Company Information

**Legal Name**: Bioptic, Inc.
**Industry**: Biotechnology, AI Software
**Employees**: {"as_of":"2025","range":"Not disclosed"}
**Focus**: Development of vertical AI agents for the biopharmaceutical industry, automating processes of asset scouting, evaluation, and licensing of drug assets globally. The platform combines molecular data, clinical evidence, and deal economics into a unified AI-driven decision-making system.
**Website**: https://agents.bioptic.io

## Scientific Background

```yaml
ai_necessity: "AI is essential because: (1) Human researchers cannot systematically process information from 100+ languages and millions of sources in real-time, (2) Virtual screening of 100+ billion compounds requires computational approaches, (3) Multi-agent systems can simultaneously evaluate multiple aspects (molecular properties, clinical data, market conditions, competitive landscape), (4) AI agents can autonomously monitor and track changes in real-time, (5) Automated due diligence and report generation compresses timelines from weeks to hours."
problem_statement: Traditional pharmaceutical asset discovery and evaluation is time-consuming, labor-intensive, and limited by human capacity to process vast amounts of data across multiple languages and sources. The process of identifying, evaluating, and licensing drug assets typically takes weeks or months, with significant manual effort required for due diligence, market analysis, and deal preparation.
biological_rationale: "Bioptic's platform addresses the bottleneck in pharmaceutical asset discovery and evaluation. The B1, B2, B3 models enable rapid evaluation of drug candidates by predicting efficacy, binding, and ADMET properties before expensive experimental validation. This accelerates the identification of promising candidates for aging-related and other therapeutic applications."
comparison_with_alternatives:
  biotic_advantages:
  - 100+ language coverage vs. typically English-only
  - Hours for due diligence vs. weeks traditional
  - Autonomous real-time monitoring vs. periodic manual checks
  - Multi-agent verification vs. single-source information
  - Integrated platform vs. fragmented tools
  - Proprietary validated models vs. generic predictions
  traditional_methods: Traditional asset scouting relies on manual literature review, limited language coverage, and weeks-long due diligence processes. Virtual screening typically requires extensive computational resources and time.
```

## Lessons Learned

### Achievements

- Developed vertical AI agents platform for pharmaceutical asset discovery and evaluation
- Created proprietary B1, B2, B3 models validated with laboratory testing
- Demonstrated real-world use case identifying licensing opportunities (July 2025)
- Filed patent application for LRRK2 virtual screening system (April 2025)
- Established pipeline with 2 proprietary and 4 collaborative programs
- Enabled due diligence report generation in hours vs. weeks traditional

### Impact on Field

Bioptic demonstrates how vertical AI agents can transform pharmaceutical asset discovery and evaluation. The platform's ability to process 100+ languages, generate due diligence reports in hours, and autonomously monitor global pharmaceutical developments represents a significant acceleration of the drug discovery and licensing process. The proprietary B1, B2, B3 models provide validated predictions that can guide early-stage decision-making, potentially accelerating the identification of promising candidates for aging-related and other therapeutic applications.

## Organizations

### Bioptic
**Legal Name**: Bioptic, Inc.
**Role in Project**: primary
**Role Description**: Primary organization developing the BIOPTIC® AI Agents Platform
**Organization Type**: company
**Status**: operational
**Website**: https://agents.bioptic.io
**Description**: Development of vertical AI agents for the biopharmaceutical industry, automating processes of asset scouting, evaluation, and licensing of drug assets globally. The platform combines molecular data, clinical evidence, and deal economics into a unified AI-driven decision-making system.
**Focus**: Development of vertical AI agents for the biopharmaceutical industry, automating processes of asset scouting, evaluation, and licensing of drug assets globally. The platform combines molecular data, clinical evidence, and deal economics into a unified AI-driven decision-making system.

## Locations

### Bioptic Headquarters
**Type**: headquarters
**Address**: Not disclosed
**Country**: USA
**Organizations**: Bioptic

## Products

### OPT-LR42
**Alternative Names**: LRRK2 Inhibitor Program
**Type**: drug
**Status**: Discovery/Preclinical
**Development Stage**: preclinical
**Role in Project**: secondary
**Relationship Description**: LRRK2 inhibitor program for Parkinson's disease
**Description**: Fully proprietary program started in May 2024, targeting Parkinson's disease through LRRK2 inhibition. In April 2025, Bioptic filed a patent application for their advanced virtual screening system targeting LRRK2 inhibition. The system enables rapid analysis of billions of molecules, accelerating the process of discovering new therapeutics. Program progressing from hit identification to preclinical studies using Bioptic's AI platform.
**Mechanism of Action**: LRRK2 (Leucine-rich repeat kinase 2) inhibitor
**Target**: LRRK2 protein
**Pathway**: Neurodegenerative pathway
**Indications**: [
  {
    "status": "Pre-IND",
    "primary": "Parkinson's Disease"
  }
]
**Technical Details**:
```yaml
notes: "Fully proprietary program started in May 2024, targeting Parkinson's disease through LRRK2 inhibition. Program progressing from hit identification to preclinical studies using Bioptic's AI platform."
patent:
  title: Advanced Virtual Screening System for LRRK2 Inhibition
  description: "Patent application for virtual screening system targeting LRRK2 inhibition for neurodegenerative diseases like Parkinson's disease"
  application_date: April 2025
start_date: May 2024
regulatory_status: Pre-IND
```

### BIOPTIC® AI Agents Platform
**Alternative Names**: BIOPTIC, Bioptic AI Agents
**Type**: platform
**Status**: Operational
**Development Stage**: operational
**Role in Project**: primary
**Relationship Description**: Primary AI agents platform for pharmaceutical asset discovery and evaluation
**Description**: Vertical AI agents platform for the biopharmaceutical industry that automates processes of asset scouting, evaluation, and licensing of drug assets globally. The platform combines molecular data, clinical evidence, and deal economics into a unified AI-driven decision-making system. AI agents act as digital employees capable of thinking like biologists, medicinal chemists, pharmacologists, and clinicians, autonomously monitoring vast and diverse data to provide critical insights.
**Capabilities**:
- Multi-language asset scouting (100+ languages)
- Automated due diligence report generation
- Real-time monitoring of clinical trials, patents, and regulatory changes
- Virtual screening of 100+ billion compounds
- ADMET prediction and compound evaluation
- Market analysis and commercialization planning
**Components**:
```yaml
-
  name: Asset Scouting Agent
  description: AI agent that scans scientific publications, regulatory documents, and news sources in over 100 languages to identify and cluster potential deals. Provides accurate identification by indication, targets, modalities, or molecules with clean, fully referenced results.
  technical_details:
  ai_methods:
  - Natural Language Processing
  - Multi-language Processing
  - Information Extraction
  - Clustering Algorithms
  - Knowledge Graph Construction
  capabilities:
  - Scan scientific publications in 100+ languages
  - Monitor regulatory documents globally
  - Track news sources for potential deals
  - Identify and cluster potential licensing opportunities
  - Provide fully referenced results with citations
  - Autonomous monitoring of clinical trials, patents, licensed deals, and regulatory changes in real-time
  performance_metrics:
  accuracy: High accuracy with multi-agent quality checks
  language_support: 100+ languages
  monitoring_frequency: Real-time
-
  name: In-Licensing Agent
  description: AI agent that ranks the most suitable external assets, prepares deal terms, and automates interactions. Helps pharmaceutical companies identify and evaluate external drug candidates for licensing opportunities.
  technical_details:
  ai_methods:
  - Ranking Algorithms
  - Deal Term Optimization
  - Automated Communication
  - Risk Assessment
  capabilities:
  - Rank external assets by suitability
  - Prepare deal terms automatically
  - Automate interaction processes
  - Evaluate asset fit for company portfolio
  - Assess competitive landscape
-
  name: Due Diligence Agent
  description: AI agent that compiles risk reports based on clinical trial data, patents, and competitive information within hours. Provides comprehensive due diligence reports for pharmaceutical asset evaluation.
  technical_details:
  ai_methods:
  - Risk Analysis
  - Data Integration
  - Report Generation
  - Pattern Recognition
  capabilities:
  - Compile risk reports in hours (vs. weeks traditional)
  - Analyze clinical trial data
  - Evaluate patent landscape
  - Assess competitive information
  - Identify potential risks and opportunities
  - Generate comprehensive due diligence reports
  performance_metrics:
  report_generation_time: Hours (vs. weeks traditional)
  data_sources_integrated: Clinical trials, patents, competitive intelligence
-
  name: Commercialization Agent
  description: AI agent that evaluates markets, models pricing and accessibility, and develops product launch scenarios. Helps pharmaceutical companies plan commercialization strategies for drug assets.
  technical_details:
  ai_methods:
  - Market Analysis
  - Pricing Models
  - Accessibility Prediction
  - Scenario Planning
  - Economic Modeling
  capabilities:
  - Evaluate market opportunities
  - Model pricing strategies
  - Predict accessibility and reimbursement
  - Develop product launch scenarios
  - Assess market competition
  - Optimize commercialization strategies
-
  name: B1 Model
  description: Ligand-oriented model for rapid screening of extensive compound libraries, predicting efficacy, safety, and manufacturability characteristics of compounds in seconds. Enables fast virtual screening of billions of compounds.
  technical_details:
  ai_methods:
  - Ligand-based Virtual Screening
  - Machine Learning
  - Property Prediction
  validation: Validated with laboratory testing and PLINDER
  capabilities:
  - Rapid screening of 100+ billion compound libraries
  - Predict efficacy of compounds
  - Predict safety profiles
  - Predict manufacturability characteristics
  - Screen compounds in seconds
  - Use proprietary ligand data
  performance_metrics:
  library_size: 100+ billion compounds
  screening_speed: Seconds per compound
  prediction_accuracy: High accuracy with laboratory validation
-
  name: B2 Model
  description: Sequence-based model that predicts binding compounds for new targets with high accuracy. Identifies potent, selective compounds with high validity for novel drug targets.
  technical_details:
  ai_methods:
  - Sequence-based Prediction
  - Binding Affinity Prediction
  - Target-ligand Interaction Modeling
  validation: Validated with laboratory testing
  capabilities:
  - Predict binding compounds for new targets
  - Identify potent compounds
  - Identify selective compounds
  - High accuracy predictions
  - High validity predictions
  - Novel target support
  performance_metrics:
  validity: High validity
  target_novelty: Supports novel targets
  prediction_accuracy: High accuracy
-
  name: B3 Model
  description: Universal ADMET predictor providing fast and comprehensive ADME/Tox profiles for early identification of potential problems. Predicts absorption, distribution, metabolism, excretion, and toxicity properties of compounds.
  technical_details:
  ai_methods:
  - ADMET Prediction
  - Pharmacokinetic Modeling
  - Toxicity Prediction
  - Machine Learning
  validation: Validated with laboratory testing
  capabilities:
  - Predict absorption properties
  - Predict distribution properties
  - Predict metabolism properties
  - Predict excretion properties
  - Predict toxicity profiles
  - Fast comprehensive profiling
  - Early problem identification
  performance_metrics:
  early_detection: Early identification of potential problems
  prediction_speed: Fast
  profile_completeness: Comprehensive
```
**Technical Details**:
```yaml
key_features:
  - Multi-agent quality checks with internal verification
  - Citations and audit of numerical data
  - Curated database using only high-quality, licensed sources
  - Feedback loop with regular reinforcement learning
  - Autonomous monitoring of clinical trials, patents, licensed deals, and regulatory changes
  - No hallucinations - multi-agent verification system
  - Scientific accuracy validated with laboratory testing and PLINDER
  - Integrated tools for computer-aided drug design and ADME/Tox prediction
  - Proprietary data on ligands, assays, and clinical trials
technologies:
  - AI Agents
  - Multi-agent Systems
  - Natural Language Processing
  - Machine Learning
  - Ligand-based Virtual Screening
  - Sequence-based Prediction
  - ADMET Prediction
  - Knowledge Graphs
  - Reinforcement Learning
  - Computer-aided Drug Design
ai_methodology:
  agent_system:
  description: Vertical AI agents that act as digital employees, capable of autonomous operation and domain-specific thinking
  capabilities:
  - Autonomous monitoring of vast and diverse data
  - Multi-language processing (100+ languages)
  - Real-time tracking of clinical trials, patents, deals, and regulatory changes
  - Multi-agent quality checks to prevent hallucinations
  - Internal verification and audit of numerical data
  - Continuous learning through reinforcement learning feedback loops
  data_sources:
  public:
  - Scientific publications (100+ languages)
  - News sources
  - Regulatory filings
  licensed:
  - Regulatory documents
  - Clinical trial databases
  - Patent databases
  - Market data
  proprietary:
  - Ligand databases
  - Assay data
  - Clinical trial data
  model_training:
  b1_model: Trained on proprietary ligand data, validated with laboratory testing and PLINDER
  b2_model: Trained on sequence data for binding prediction, validated with laboratory testing
  b3_model: Trained on ADMET data, validated with laboratory testing
validation_process:
  quality_control: Multi-agent quality checks with internal verification, citations, and audit of numerical data to prevent hallucinations
  plinder_validation: Models validated with PLINDER
  laboratory_validation: All models (B1, B2, B3) validated with laboratory testing
  real_world_validation: Platform used in real-world pharmaceutical asset evaluation scenarios, demonstrated in July 2025 use case
platform_architecture:
  components:
  - Asset Scouting Agent - Multi-language information extraction and clustering
  - In-Licensing Agent - Automated ranking and deal term preparation
  - Due Diligence Agent - Risk analysis and report generation
  - Commercialization Agent - Market analysis and scenario planning
  - B1 Model - Ligand-based virtual screening
  - B2 Model - Sequence-based binding prediction
  - B3 Model - ADMET prediction
  description: Multi-agent AI platform with specialized agents for different pharmaceutical workflows. Each agent operates autonomously and can think like domain experts (biologists, medicinal chemists, pharmacologists, clinicians).
  integration: All components integrated into unified AI-driven decision-making system combining molecular data, clinical evidence, and deal economics
advantages_over_competitors:
  - "Proprietary data: Uses proprietary data on ligands, assays, and clinical trials"
  - "No hallucinations: Multi-agent quality control system with internal checks and audit of numerical data"
  - "Scientific accuracy: Validated with laboratory testing and PLINDER"
  - "Tool integration: Built-in tools for computer-aided drug design and ADME/Tox prediction"
  - "Curated database: Uses only high-quality, licensed sources including regulatory documents, clinical trials, and market data"
  - "Feedback loop: Continuous improvement through regular reinforcement learning including user queries and feedback"
  - "Autonomous monitoring: Agents track clinical trials, patents, licensed deals, and regulatory changes in real-time"
```

## Links

### [Bioptic LRRK2 Patent Blog Post](https://bioptic.io/blog/lrrk2-patent)
**Type**: blog_post
**Relevance**: primary
**Category**: publication
**Relationship Description**: Blog post about patent application for LRRK2 virtual screening system
**Publisher**: Bioptic
**Publication Date**: 2025-04-01
**Description**: Blog post about patent application for advanced virtual screening system targeting LRRK2 inhibition

### [Bioptic Contact](https://bioptic.io/contact)
**Type**: website
**Relevance**: secondary
**Category**: source
**Relationship Description**: Contact information page
**Publisher**: Bioptic
**Description**: Contact information page

### [Bioptic Pipeline](https://bioptic.io/pipeline)
**Type**: website
**Relevance**: primary
**Category**: source
**Relationship Description**: Pipeline page showing proprietary and collaborative programs
**Publisher**: Bioptic
**Description**: Pipeline page showing proprietary and collaborative programs

### [Bioptic About](https://bioptic.io/about)
**Type**: website
**Relevance**: primary
**Category**: source
**Relationship Description**: About page with company information and team background
**Publisher**: Bioptic
**Description**: About page with company information and team background

### [Bioptic Technology](https://bioptic.io/technology)
**Type**: website
**Relevance**: primary
**Category**: source
**Relationship Description**: Technology page describing AI agents and models
**Publisher**: Bioptic
**Description**: Technology page describing AI agents and models

### [Bioptic - Official Website](https://bioptic.io)
**Type**: website
**Relevance**: primary
**Category**: source
**Relationship Description**: Official company website
**Publisher**: Bioptic
**Description**: Official company website

## Events

### OPT-LR42 Program Launch
**Date**: 2024-05-01
**Type**: program_launch
**Description**: Started OPT-LR42 program targeting Parkinson's disease through LRRK2 inhibition
**Details**:
```yaml
type: Program Launch
details: "Initiated fully proprietary program for developing LRRK2 inhibitor for Parkinson's disease treatment"
```

### LRRK2 Virtual Screening System Patent Application
**Date**: 2025-04-01
**Type**: patent_application
**Description**: Filed patent application for advanced virtual screening system targeting LRRK2 inhibition
**Details**:
```yaml
type: Patent Application
details: "Patent application for virtual screening system aimed at inhibiting LRRK2, a key target in neurodegenerative diseases such as Parkinson's disease. The system enables rapid analysis of billions of molecules, accelerating the discovery of new therapeutics."
```

### Use Case Demonstration - PD-(L)1 Asset Identification
**Date**: 2025-07-01
**Type**: milestone
**Description**: BIOPTIC® agents conducted research identifying Phase II PD-(L)1 assets in oncology without direct competitors in the EU
**Details**:
```yaml
type: Use Case Demonstration
details: Demonstrated platform capabilities by identifying licensing opportunities including Camrelizumab from Innovent and Socazolimab from Junshi, with upcoming key events in Q4 2025 and Q3 2025 respectively
```
